Succeeder(SH:688338) Xin Lang Cai Jing·2025-10-31 15:14Company Overview - Founded on May 28, 2003, and listed on the Shanghai Stock Exchange on August 6, 2020, the company is a leading player in the field of thrombus and hemostasis in vitro diagnostics in China, possessing a full industry chain advantage [1] - The company primarily engages in the research, development, production, and sales of diagnostic instruments, reagents, and consumables related to thrombus and hemostasis [1] Financial Performance - For Q3 2025, the company's revenue was 196 million, ranking 33rd out of 39 in the industry, while the net profit was approximately 64.5 million, ranking 13th out of 39 [2] - The industry leader, New Industries, reported revenue of 3.43 billion, and the second leader, Antu Bio, reported revenue of 3.13 billion, with the industry average revenue being 708 million and the median at 330 million [2] - The net profit of the industry leader, Ji'an Medical, was 1.59 billion, and the second leader, New Industries, had a net profit of 1.21 billion, with the industry average net profit at 110 million and the median at 26.19 million [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 4.67%, down from 5.25% in the previous year, which is significantly lower than the industry average of 18.29% [3] - The gross profit margin for Q3 2025 was 62.22%, slightly up from 62.13% in the previous year, and higher than the industry average of 56.20% [3] Executive Compensation - The chairman, Wu Shiming, received a salary of 1.12 million in 2024, a decrease of 2,300 from 2023 [4] - The general manager, Wang Hai, earned 450,200 in 2024, also a decrease of 2,300 from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 3.44% to 7,012, while the average number of circulating A-shares held per account decreased by 3.32% to 15,100 [5]